This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEB7Q0U9_M.jpg
With approximately $9.44 billion in net assets, ARKG is one of the largest actively managed ETFs in the industry, with at least 80% of the funds invested directly in relevant domestic and foreign equity securities. Wood expects DNA sequencing to emerge as a global disruptive trend this year itself. This has motivated more investors to bet on the healthcare industry through ARKG. Consequently, ARKG’s NAV has increased 186% over the past year. Novartis AG (NVS), Vertex Pharmaceuticals Incorporated (VRTX) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are among ARKG’s top seven holdings ARKG. And given their impressive innovative capabilities and solid financials, these companies are expected to lead the healthcare revolution through genomics globally.
Wood recently observed in a CNBC interview that, “We can honestly say that until now more than half of all healthcare decisions were in some part made through guesses or experiences. Now we’re going to have the data.” The global biotechnology market is expected to grow at a CAGR of 15.8% over the next seven years to reach $752.88 billion by 2028.
